Androgen-AR axis in primary and metastatic prostate cancer: chasing steroidogenic enzymes for therapeutic intervention

Abstract

Androgens play an important role in prostate cancer (PCa) development and progression. Although androgen deprivation therapy remains the front-line treatment for advanced prostate cancer, patients eventually relapse with the lethal form of the disease. The prostate tumor microenvironment is characterised by elevated tissue androgens that are capable of activating the androgen receptor (AR). Inhibiting the steroidogenic enzymes that play vital roles in the biosynthesis of testosterone (T) and dihydrotestosterone (DHT) seems to be an attractive strategy for PCa therapies. Emerging data suggest a role for the enzymes mediating pre-receptor control of T and DHT biosynthesis by alternative pathways in controlling intratumoral androgen levels, and thereby influencing PCa progression. This supports the idea for the development of multi-targeting strategies, involving both dual and multiple inhibitors of androgen-metabolising enzymes that are able to affect androgen synthesis and signalling at different points in the biosynthesis. In this review, we will focus on CYP17A1, AKR1C3, HSD17B3 and SRD5A, as these enzymes play essential roles in all the three androgenic pathways. We will review also the AR as an additional target for the design of bifunctional drugs. Targeting intracrine androgens and AKR1C3 have potential to overcome enzalutamide and abiraterone resistance and improve survival of advanced prostate cancer patients.

Keywords

AKR1C3 / HSD17B3 / CYP17A1 / SRD5A / androgen receptor / castration-resistant prostate cancer / inhibitors / bifunctional molecules

References

[1] Siegel RL,Jemal A.Cancer statistics, 2016..CA Cancer J Clin2016;66:7-30

[2] Nelson PS,Arnold H,Bonham M,Hood L.The program of androgen-responsive genes in neoplastic prostate epithelium..Proc Natl Acad Sci U S A2002;99:11890-5 PMCID:PMC129364

[3] Saad F.Androgen deprivation therapy and secondary hormone therapy in the management of hormone-sensitive and castration-resistant prostate cancer..Urology2015;86:852-61

[4] Huggins C,Hodges CV.Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland..Arch Surg1941;43:209

[5] James ND,Clarke NW,De Bono JS,Hetherington J,Jones RJ,Lester JF,Parker CC,Ritchie AW,Strebel RT,Mason MD.Survival with newly diagnosed metastatic prostate cancer in the "docetaxel era": data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019)..Eur Urol2015;67:1028-38

[6] Imamura Y.Androgen receptor targeted therapies in castration-resistant prostate cancer: bench to clinic..Int J Urol2016;23:654-65

[7] Seisen T,Gomez F,Shariat SF,Spano JP,Cussenot O.A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer..Cancer Treat Rev2016;48:25-33

[8] Kumagai J,Erkens-Schulze S,Steenbergen J,Homma Y,van Weerden WM.Intratumoral conversion of adrenal androgen precursors drives androgen receptor-activated cell growth in prostate cancer more potently than de novo steroidogenesis..Prostate2013;73:1636-50

[9] Penning TM.Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC)..J Steroid Biochem Mol Biol2015;153:105-13 PMCID:PMC4568163

[10] Sakai M,Aprikian AG,Papadopoulos V.De novo steroid biosynthesis in human prostate cell lines and biopsies..Prostate2016;76:575-87

[11] Titus MA,Lih FB,Mohler JL.Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer..Clin Cancer Res2005;11:4653-7

[12] Zhang W,Liu N,Yang T.Insights into chemoresistance of prostate cancer..Int J Biol Sci2015;11:1160-70 PMCID:PMC4551752

[13] Cai C.Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy..Endocr Relat Cancer2011;18:R175-82 PMCID:PMC3815562

[14] Fankhauser M,Hong MKH,Macintyre G,Pedersen JS,Hovens CM.Canonical androstenedione reduction is the predominant source of signaling androgens in hormone-refractory prostate cancer..Clin Cancer Res2014;20:5547-57

[15] Montgomery RB,Vessella R,Kalhorn TF,True LD.Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth..Cancer Res2008;68:4447-54 PMCID:PMC2536685

[16] Miller WL.The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders..Endocr Rev2011;32:81-151 PMCID:PMC3365799

[17] Stanbrough M,Ross K,Rubin MA,Febbo PG.Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer..Cancer Res2006;66:2815-25

[18] Chang KH,Papari-Zareei M,Zhao YD,Sharifi N.Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer..Proc Natl Acad Sci U S A2011;108:13728-33 PMCID:PMC3158152

[19] Campbell TJ,Figg WD.Dihydrotestosterone synthesis from adrenal precursors does not involve testosterone in castration-resistant prostate cancer..Cancer Biol Ther2012;13:237-8 PMCID:PMC3367713

[20] Wilson JD,Leihy MW,Estabrook RW,Shaw G.5alpha-androstane-3alpha,17beta-diol is formed in tammar wallaby pouch young testes by a pathway involving 5alpha-pregnane-3alpha,17alpha-diol-20-one as a key intermediate..Endocrinology2003;144:575-80

[21] Auchus RJ.The backdoor pathway to dihydrotestosterone..Trends Endocrinol Metab2004;15:432-8

[22] Locke JA,Lubik AA,Hendy SC,Ettinger SL,Nelson CC.Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer..Cancer Res2008;68:6407-15

[23] Locke JA,Adomat HH,Gleave ME.Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts..J Steroid Biochem Mol Biol2009;115:126-36

[24] Stuchbery R,Hovens CM.Androgen synthesis in prostate cancer: do all roads lead to Rome?.Nat Rev Urol2017;14:49-58

[25] Missaghian E,Dick B,Alikhani-Koupaei R,Mullis PE,Fluck CE.Role of DNA methylation in the tissue-specific expression of the CYP17A1 gene for steroidogenesis in rodents..J Endocrinol2009;202:99-109

[26] Chung BC,Haniu M,Hall PF,Miller WL.Cytochrome P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase): cloning of human adrenal and testis cDNAs indicates the same gene is expressed in both tissues..Proc Natl Acad Sci U S A1987;84:407-11 PMCID:PMC304216

[27] Martinez-Arguelles DB.Epigenetic regulation of the expression of genes involved in steroid hormone biosynthesis and action..Steroids2010;75:467-76 PMCID:PMC2860648

[28] Fluck CE.GATA-4 and GATA-6 modulate tissue-specific transcription of the human gene for P450c17 by direct interaction with Sp1..Mol Endocrinol2004;18:1144-57

[29] Yoshimoto FK.The diverse chemistry of cytochrome P450 17A1 (P450c17, CYP17A1)..J Steroid Biochem Mol Biol2015;151:52-65 PMCID:PMC4456341

[30] Estrada DF,Scott EE.Substrate-modulated cytochrome P450 17A1 and cytochrome b5 interactions revealed by NMR..J Biol Chem2013;288:17008-18 PMCID:PMC3675632

[31] Manenda MS,Masselot-Joubert L,Shi R.Androgen-metabolizing enzymes: a structural perspective..J Steroid Biochem Mol Biol2016;161:54-72

[32] DeVore NM.Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001..Nature2012;482:116-9 PMCID:PMC3271139

[33] Petrunak EM,Porubsky PR.Structures of human steroidogenic cytochrome P450 17A1 with substrates..J Biol Chem2014;289:32952-64 PMCID:PMC4239641

[34] Estrada DF,Laurence JS.Human cytochrome P450 17A1 conformational selection: modulation by ligand and cytochrome b5..J Biol Chem2014;289:14310-20 PMCID:PMC4022897

[35] Gomez L,Lamb DJ.CYP17A1 inhibitors in castration-resistant prostate cancer..Steroids2015;95:80-7 PMCID:PMC4323677

[36] Njar VCO.Discovery and development of galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer..J Med Chem2015;58:2077-87

[37] Handratta VD,Njar VC,Kataria R,Newman DJr,Guo Z,Brodie AM.Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model..J Med Chem2005;48:2972-84

[38] Ryan CJ,de Bono JS,Logothetis CJ,Fizazi K,Piulats JM,Carles J,Basch E,Saad F,Van Poppel H,Suttmann H,Flaig TW,Yu EY,Pantuck A,Higano CS,Park Y,Griffin T,Rathkopf DE.Abiraterone in metastatic prostate cancer without previous chemotherapy..N Engl J Med2013;368:138-48 PMCID:PMC3683570

[39] Kaku T,Ojida A,Adachi M,Hara T,Kusaka M,Asahi S,Tasaka A.Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer..Bioorg Med Chem2011;19:6383-99

[40] Toren PJ,Pham S,Adomat H,Zoubeidi A,Gleave ME.Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer..Mol Cancer Ther2015;14:59-69

[41] Larsen M,Rasmussen TB,Styrishave B,Jorgensen FS.Structure-based optimisation of non-steroidal cytochrome P450 17A1 inhibitors..Chem Commun (Camb)2017;53:3118-21

[42] Bonomo S,Petrunak EM,Styrishave B,Olsen L.Promising tools in prostate cancer research: selective non-steroidal cytochrome P450 17A1 inhibitors..Sci Rep2016;6:29468 PMCID:PMC4942611

[43] Wang M,Gu S,Zhu Z,Zhu J.Discovery of novel 1,2,3,4-tetrahydrobenzo[4, 5]thieno[2, 3-c]pyridine derivatives as potent and selective CYP17 inhibitors..Eur J Med Chem2017;132:157-72

[44] Penning TM,Jez JM,Ma H,Ratnam K.Structure-function aspects and inhibitor design of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3)..Mol Cell Endocrinol2001;171:137-49

[45] Sun SQ,Gao XS,Yu H,Yu H,Li Y,Zhou D.Overexpression of AKR1C3 significantly enhances human prostate cancer cells resistance to radiation..Oncotarget2016;7:48050-8 PMCID:PMC5216999

[46] Endo S,Matsunaga T,El-Kabbani O,Ikari A,Kitade Y.Synthesis of non-prenyl analogues of baccharin as selective and potent inhibitors for aldo-keto reductase 1C3..Bioorg Med Chem2014;22:5220-33

[47] Lovering AL,Bunce CM,Cummings SM.Crystal structures of prostaglandin D2 11-ketoreductase (AKR1C3) in complex with the nonsteroidal anti-inflammatory drugs flufenamic acid and indomethacin..Cancer Res2004;64:1802-10

[48] Flanagan JU,Teague RM,Turnbull AP.Crystal structures of three classes of non-steroidal anti-inflammatory drugs in complex with aldo-keto reductase 1C3..PLoS One2012;7:e43965 PMCID:PMC3429426

[49] Penning TM,Jez JM,Lin HK,Moore M,Ratnam K.Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones..Biochem J2000;351:67-77 PMCID:PMC1221336

[50] Burczynski ME,Penning TM.Expression and characterization of four recombinant human dihydrodiol dehydrogenase isoforms: oxidation of trans-7, 8-dihydroxy-7,8-dihydrobenzo[a]pyrene to the activated o-quinone metabolite benzo[a]pyrene-7,8-dione..Biochemistry1998;37:6781-90

[51] Byrns MC,Penning TM.Inhibitors of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights..J Steroid Biochem Mol Biol2011;125:95-104 PMCID:PMC3047600

[52] Adeniji AO,Penning TM.AKR1C3 as a target in castrate resistant prostate cancer..J Steroid Biochem Mol Biol2013;137:136-49 PMCID:PMC3805777

[53] Skarydova L,Chlebek J,Kosanova K,Hostalkova A,Cahlikova L.Isoquinoline alkaloids as a novel type of AKR1C3 inhibitors..J Steroid Biochem Mol Biol2014;143:250-8

[54] Tian Y,Wang Y,Xu D,Li Y.Berberine inhibits androgen synthesis by interaction with aldo-keto reductase 1C3 in 22Rv1 prostate cancer cells..Asian J Androl2016;18:607-12 PMCID:PMC4955188

[55] Akao Y,Matsumoto K,Nishizawa K,Araki Y,Nozawa Y.Cell growth inhibitory effect of cinnamic acid derivatives from propolis on human tumor cell lines..Biol Pharm Bull2003;26:1057-9

[56] Endo S,Kanamori A,Nagai H,El-Kabbani O,Ohta S.Selective inhibition of human type-5 17beta-hydroxysteroid dehydrogenase (AKR1C3) by baccharin, a component of Brazilian propolis..J Nat Prod2012;75:716-21

[57] Ogihara T,Tsuji A.Structural characterization of substrates for the anion exchange transporter in Caco-2 cells..J Pharm Sci1999;88:1217-21

[58] Pippione AC,Ducime A,Martina K,Frolund B,Janda KD,Lolli ML.Substituted 4-hydroxy-1,2,3-triazoles: synthesis, characterization and first drug design applications through bioisosteric modulation and scaffold hopping approaches..Medchemcomm2015;6:1285-92

[59] Sainas S,Giorgis M,Goyal P,Buccinna B,Braga RC,Andersson M,Friemann R,Al-Kadaraghi S,Lolli ML.Design, synthesis, biological evaluation and X-ray structural studies of potent human dihydroorotate dehydrogenase inhibitors based on hydroxylated azole scaffolds..Eur J Med Chem2017;129:287-302

[60] Pippione AC,Bonanni D,Marini E,Costale A,Pors K,Boschi D,Lolli ML.Hydroxytriazole derivatives as potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approach..Eur J Med Chem2017;139:936-46

[61] Heinrich DM,Jamieson SM,Rigoreau LJ,Raynham T,Denny WA.Synthesis and structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3..Eur J Med Chem2013;62:738-44

[62] Jamieson SM,Heinrich D,Silva S,Turnbull AP,Trivier E,Samlal SS,Schroeder E,Flanagan JU.3-(3,4-Dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic acids: highly potent and selective inhibitors of the type 5 17-beta-hydroxysteroid dehydrogenase AKR1C3..J Med Chem2012;55:7746-58

[63] Yin YD,Brooke DG,Denny WA.The activity of SN33638, an inhibitor of AKR1C3, on testosterone and 17beta-estradiol production and function in castration-resistant prostate cancer and ER-positive breast cancer..Front Oncol2014;4:159 PMCID:PMC4061482

[64] Zhou W.AKR1C3 inhibition therapy in castration-resistant prostate cancer and breast cancer: lessons from responses to SN33638..Front Oncol2014;4:162 PMCID:PMC4066440

[65] Flanagan JU,Heinrich DM,Silva S,Trivier E,Raynham T,Denny WA.Morpholylureas are a new class of potent and selective inhibitors of the type 5 17-beta-hydroxysteroid dehydrogenase (AKR1C3)..Bioorg Med Chem2014;22:967-77

[66] Kikuchi A,Azami H,Niimi T,Kuromitsu S,Heeringa M,Enjo K.In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17beta-hydroxysteroid dehydrogenase type 5 (17betaHSD5; AKR1C3)..Invest New Drugs2014;32:860-70

[67] Yepuru M,Kulkarni A,Barrett CM,Steiner MS,Dalton JT.Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth..Clin Cancer Res2013;19:5613-25

[68] Loriot Y,Jones RJ,Molife RL,James ND,Heeringa M,Holtkamp GM,De Bono JS.Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study..Invest New Drugs2014;32:995-1004

[69] Enzalutamide and indomethacin in treating patients with recurrent or metastatic hormone-resistant prostate cancer. In: ClinicalTrials.gov; Identifier: NCT02935205. Available from: https://clinicaltrials.gov/ct2/show/NCT02935205. [Last accessed on 13 Nov 2017]

[70] A phase II neoadjuvant study of ARN-509, abiraterone acetate, prednisone, degarelix and indomethacin in men with localized prostate cancer pre-prostatectomy. Available from: http://www.centerwatch.com/clinical-trials/listings/98162/stage-iii-prostate-adenocarcinoma-phase-ii-neoadjuvant-study/?&radius=50. [Last accessed on 13 Nov 2017]

[71] Guise CP,Singleton RS,Connolly J,Fox SB,Harvey J,Donate F,Patterson AV.The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3..Cancer Res2010;70:1573-84

[72] Manesh DM,Evans K,Toscan CE,Hedrick A,Marshall GM,Kurmasheva RT,Houghton PJ,Carol H.AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia..Blood2015;126:1193-202 PMCID:PMC4559932

[73] Marchais-Oberwinkler S,Moller G,Negri M,Spadaro A,Wetzel M,Frotscher M,Adamski J.17beta-Hydroxysteroid dehydrogenases (17beta-HSDs) as therapeutic targets: protein structures, functions, and recent progress in inhibitor development..J Steroid Biochem Mol Biol2011;125:66-82

[74] Poirier D.17beta-Hydroxysteroid dehydrogenase inhibitors: a patent review..Expert Opin Ther Pat2010;20:1123-45

[75] Day JM,Purohit A.17ss-hydroxysteroid dehydrogenase inhibitors..Minerva Endocrinol2010;35:87-108

[76] Olusanjo MS.Inhibitors of 17-hydroxysteroid dehydrogenase type 3 (17-beta-HSD 3)..Drugs Future2009;34:555

[77] Ning X,Deng H,Huang Y,Fu Y,Zhang S.Development of 17β-hydroxysteroid dehydrogenase type 3 as a target in hormone-dependent prostate cancer therapy..Steroids2017;121:10-6

[78] Fink BE,Tokarski JS,Misra R,Kimball SD,Norris D,You D,Lorenzi MV.Identification of a novel series of tetrahydrodibenzazocines as inhibitors of 17beta-hydroxysteroid dehydrogenase type 3..Bioorg Med Chem Lett2006;16:1532-6

[79] Vicker N,Heaton WB,Bailey HV,Springall JS,Tutill HJ,Purohit A.The design of novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitors..Mol Cell Endocrinol2009;301:259-65

[80] Nashev LG,Laggner C,Langer T,Odermatt A.The UV-filter benzophenone-1 inhibits 17beta-hydroxysteroid dehydrogenase type 3: virtual screening as a strategy to identify potential endocrine disrupting chemicals..Biochem Pharmacol2010;79:1189-99

[81] Schuster D,Kirchmair J,Markt P,Strohle F,Wolber G,Langer T,Adamski J.Identification of chemically diverse, novel inhibitors of 17beta-hydroxysteroid dehydrogenase type 3 and 5 by pharmacophore-based virtual screening..J Steroid Biochem Mol Biol2011;125:148-61

[82] Guzi TJ,Doll RJ,Girijavallabhan VM.Preparation of 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine derivatives as 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases..2004;Kenilworth, USASchering Corporation72

[83] Day JM,Tutill HJ,Sharland CM,Vicker N,Reed MJ.STX2171, a 17beta-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model..Endocr Relat Cancer2013;20:53-64

[84] Harada K,Tomigahara Y,Takahashi J,Inoue S.Coumarins as novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for potential treatment of prostate cancer..Bioorg Med Chem Lett2010;20:272-5

[85] Harada K,Abe J,Conception A,Okada S.Discovery of potent and orally bioavailable 17β-hydroxysteroid dehydrogenase type 3 inhibitors..Bioorg Med Chem2012;20:3242-54

[86] Ohno S,Nakajin S.Triphenyltin and tributyltin inhibit pig testicular 17beta-hydroxysteroid dehydrogenase activity and suppress testicular testosterone biosynthesis..Steroids2005;70:645-51

[87] Titus MA,Kozyreva OG,Godoy A,Mohler JL.5α-reductase type 3 enzyme in benign and malignant prostate..Prostate (Hoboken, NJ, U S)2014;74:235-49

[88] Azzouni F,Li Y.The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases..Adv Urol2012;2012:530121 PMCID:PMC3253436

[89] Li J,Wang Z,Maity SN,Logothetis CJ,Kim J.Androgen regulation of 5alpha-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention..PLoS One2011;6:e28840 PMCID:PMC3237548

[90] Gormley GJ,Bruskewitz RC,Walsh PC,Andriole GL,Bracken BR,Vaughan ED,Taylor A,Ng J.The effect of finasteride in men with benign prostatic hyperplasia. 1992..J Urol2002;167:1102-8

[91] Roehrborn CG,Nickel JC,Andriole G.Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia..Urology2002;60:434-41

[92] Faller B,Nick H.Finasteride: a slow-binding 5 alpha-reductase inhibitor..Biochemistry1993;32:5705-10

[93] Aggarwal S,Verma A,Kumar M.An overview on 5alpha-reductase inhibitors..Steroids2010;75:109-53

[94] Clark RV,Cunningham GR,Morrill BB.Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor..J Clin Endocrinol Metab2004;89:2179-84

[95] Salvador JA,Silvestre SM.Steroidal 5alpha-reductase and 17alpha-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases..J Steroid Biochem Mol Biol2013;137:199-222

[96] Holt DA,Oh HJ,Heaslip JI,Lan-Hargest HY.Inhibition of steroid 5 alpha-reductase by unsaturated 3-carboxysteroids..J Med Chem1990;33:943-50

[97] Yao Z,Zhang M,Nicklaus MC.Discovery of a novel hybrid from finasteride and epristeride as 5α-reductase inhibitor..Bioorg Med Chem Lett2011;21:475-8

[98] Aggarwal S,Bhardwaj TR,Hartmann RW.Synthesis and biological evaluation of novel unsaturated carboxysteroids as human 5alpha-reductase inhibitors: a legitimate approach..Eur J Med Chem2012;54:728-39

[99] Kim S,Ma E.Synthesis and 5α-reductase inhibitory activity of C21 steroids having 1,4-diene or 4,6-diene 20-ones and 4-azasteroid 20-oximes..Molecules2012;17:355-68

[100] Al-Mohizea AM,Abdalla MM.5alpha-reductase inhibitors, antiviral and anti-tumor activities of some steroidal cyanopyridinone derivatives..Int J Biol Macromol2012;50:171-9

[101] Lacy JM.A tale of two trials: the impact of 5α-reductase inhibition on prostate cancer (Review)..Oncol Lett2014;8:1391-6

[102] FDA Drug Safety Communication: 5-alpha reductase inhibitors (5-ARIs) may increase the risk of a more serious form of prostate cancer. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm258314.htm. [Last accessed on 13 Nov 2017]

[103] Fleshner NE,Egerdie B,Eure G,Black L.Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial..Lancet2012;379:1103-11

[104] Schroder F,Angulo JC,Colombel M,Tammela TL,Castro R.Dutasteride treatment over 2 years delays prostate-specific antigen progression in patients with biochemical failure after radical therapy for prostate cancer: results from the randomised, placebo-controlled Avodart After Radical Therapy for Prostate Cancer Study (ARTS)..Eur Urol2013;63:779-87

[105] Ramalingam S,Njar VC.Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets..J Steroid Biochem Mol Biol2017;166:16-27

[106] Blessing AM,Rajapakshe K,Reddy Bollu L,Cheung E,Chang JT,Frigo DE.Identification of a novel coregulator, SH3YL1, that interacts with the androgen receptor N-terminus..Mol Endocrinol2015;29:1426-39 PMCID:PMC4588732

[107] Dubbink HJ,Verma CS,Berrevoets CA,Ziel-van der Made AC,Pike AC.Distinct recognition modes of FXXLF and LXXLL motifs by the androgen receptor..Mol Endocrinol2004;18:2132-50

[108] Saporita AJ,Navai N,Hahn J,Wang Z.Identification and characterization of a ligand-regulated nuclear export signal in androgen receptor..J Biol Chem2003;278:41998-2005

[109] Shang Y,Brown M.Formation of the androgen receptor transcription complex..Mol Cell2002;9:601-10

[110] Lonergan PE.Androgen receptor signaling in prostate cancer development and progression..J Carcinog2011;10:20 PMCID:PMC3162670

[111] Green SM,Nelson PS.Androgen action and metabolism in prostate cancer..Mol Cell Endocrinol2012;360:3-13 PMCID:PMC4124858

[112] Kahn B,Kyprianou N.Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer..Int J Biol Sci2014;10:588-95 PMCID:PMC4062951

[113] Shafi AA,Weigel NL.Androgen receptors in hormone-dependent and castration-resistant prostate cancer..Pharmacol Ther2013;140:223-38

[114] Jarrard DF,Shi Y,Hoff D,Chang C,Isaacs WB.Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells..Cancer Res1998;58:5310-4

[115] Nakayama T,Suzuki H,Sekita N,Mizokami A,Yatani R.Epigenetic regulation of androgen receptor gene expression in human prostate cancers..Lab Invest2000;80:1789-96

[116] Schulz WA.Epigenetic mechanisms in the biology of prostate cancer..Semin Cancer Biol2009;19:172-80

[117] Martinez-Ariza G.Recent advances in allosteric androgen receptor inhibitors for the potential treatment of castration-resistant prostate cancer..Pharm Pat Anal2015;4:387-402

[118] Lu X,Wang Y,You Q.Recent androgen receptor antagonists in prostate cancer..Mini Rev Med Chem2014;14:655-63

[119] Tran C,Clegg NJ,Watson PA,Wongvipat J,Yoo D,Wasielewska T,Chen CD,Beer TM,Scher HI,Sawyers CL.Development of a second-generation antiandrogen for treatment of advanced prostate cancer..Science2009;324:787-90 PMCID:PMC2981508

[120] Clegg NJ,Joseph JD,Ouk S,Chen Y,Bischoff ED,Aparicio A,Arora V,Qian J,Yang G,Sensintaffar J,Herbert MR,Darimont B,Smith-Jones P,Smith ND,Wu N,Rix PJ,Jung ME,Hager JH.ARN-509: a novel antiandrogen for prostate cancer treatment..Cancer Res2012;72:1494-503 PMCID:PMC3306502

[121] Fizazi K,Loriot Y.ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer..Expert Rev Anticancer Ther2015;15:1007-17 PMCID:PMC4673554

[122] Yu Z,Gao S,Shen HC.Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor..Clin Cancer Res2014;20:4075-85 PMCID:PMC4119496

[123] Bastos DA.Galeterone for the treatment of advanced prostate cancer: the evidence to date..Drug Des Devel Ther2016;10:2289-97 PMCID:PMC4956059

[124] Biron E.Recent progress in the development of protein-protein interaction inhibitors targeting androgen receptor-coactivator binding in prostate cancer..J Steroid Biochem Mol Biol2016;161:36-44

[125] Ran F,Liu Y,Li P.Recent developments in androgen receptor antagonists..Arch Pharm (Weinheim)2015;348:757-75

[126] Tice CM.Non-canonical modulators of nuclear receptors..Bioorg Med Chem Lett2016;26:4157-64

[127] Lallous N,Cherkasov A.Targeting alternative sites on the androgen receptor to treat castration-resistant prostate cancer..Int J Mol Sci2013;14:12496-519 PMCID:PMC3709796

[128] Kandil S,McGuigan C.7-Substituted umbelliferone derivatives as androgen receptor antagonists for the potential treatment of prostate and breast cancer..Bioorg Med Chem Lett2016;26:2000-4

[129] Johnson JK,Zhou J,Wang D,Eyer BR,Eisermann K,Nelson JB,Wipf P.Small molecule antagonists of the nuclear androgen receptor for the treatment of castration-resistant prostate cancer..ACS Med Chem Lett2016;7:785-90 PMCID:PMC4983742

[130] Balog A,Martin GS,Attar R,DiMarco JD,Gougoutas J,Nation A,Rossiter LM,Shan W,Spires T,Gottardis M,Vite GD.Discovery of BMS-641988, a novel androgen receptor antagonist for the treatment of prostate cancer..ACS Med Chem Lett2015;6:908-12 PMCID:PMC4538445

[131] Zhao C,Khadka DB,Lee KY.Design and synthesis of novel androgen receptor antagonists via molecular modeling..Bioorg Med Chem2016;24:789-801

[132] Yang SH,Van HT,Khadka DB,Lee K.SAR based design of nicotinamides as a novel class of androgen receptor antagonists for prostate cancer..J Med Chem2013;56:3414-8

[133] Ferroni C,Kim YS,Guerrini A,Tesei A,Cortesi M,De Cesare M,Trepel JB,Varchi G.1,4-substituted triazoles as nonsteroidal anti-androgens for prostate cancer treatment..J Med Chem2017;60:3082-93

[134] Buzon V,Estruch SB,Estebanez-Perpina E.A conserved surface on the ligand binding domain of nuclear receptors for allosteric control..Mol Cell Endocrinol2012;348:394-402

[135] Estebanez-Perpina E,Nguyen P,Mar E,Pallai P,Baxter JD,Webb P.A surface on the androgen receptor that allosterically regulates coactivator binding..Proc Natl Acad Sci U S A2007;104:16074-9 PMCID:PMC1999396

[136] Munuganti RS,Leblanc E,Singh K,Ban F,Adomat H,Andre C,Zoubeidi A,Guns ET,Cherkasov A.Identification of a potent antiandrogen that targets the BF3 site of the androgen receptor and inhibits enzalutamide-resistant prostate cancer..Chem Biol2014;21:1476-85

[137] Zhang Y,Jobbagy S,Koh JT.Antagonizing the androgen receptor with a biomimetic acyltransferase..ACS Chem Biol2016;11:2797-802 PMCID:PMC5592735

[138] Myung JK,Fernandez JG,Wang J,Yang YC,Haile S,McEwan IJ,Andersen RJ.An androgen receptor N-terminal domain antagonist for treating prostate cancer..J Clin Invest2013;123:2948-60 PMCID:PMC3696543

[139] Andersen RJ,Wang J,Haile S,Watt K,Yang YC,Williams DE,Wang Y.Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor..Cancer Cell2010;17:535-46

[140] Antonarakis ES,Luo J,Osbourne E,Sadar MD.Targeting the N-terminal domain of the androgen receptor: a new approach for the treatment of advanced prostate cancer..Oncologist2016;21:1427-35 PMCID:PMC5153341

[141] Andersen RJ.Sponging off nature for new drug leads..Biochem Pharmacol2017;139:3-14

[142] Shaffer PL,Dollins DE,Gewirth DT.Structural basis of androgen receptor binding to selective androgen response elements..Proc Natl Acad Sci U S A2004;101:4758-63 PMCID:PMC387321

[143] Diamond M,Renslo A.Androgen receptor inhibitors, including tetrahydropyrvinium derivatives and benzoxazole compounds, and their therapeutic use.Oakland, USA: University of California;2009;67

[144] Lim M,He M,Nguyen D,Alliston T.Ligand-independent and tissue-selective androgen receptor inhibition by pyrvinium..ACS Chem Biol2014;9:692-702 PMCID:PMC3962707

[145] Li H,Dalal K,Frewin K,Adomat H,Cherkasov A.Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor..J Med Chem2014;57:6458-67

[146] Dalal K,Sharma A,Ban F,Hsing M,LeBlanc E,Tomlinson Guns ES,Rennie PS.Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer..J Biol Chem2014;289:26417-29 PMCID:PMC4176249

[147] Loddick SA,Thomason AG,Walker GE,Brave SR,Stratton NC,Mouchet E,Jacobs VN,Wilson J,Bradbury RH,Gaughan L,Barry ST,Critchlow SE,Brooks AN.AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo..Mol Cancer Ther2013;12:1715-27 PMCID:PMC3769207

[148] Omlin A,van der Noll R,Niwakawa M,Graham J,Finkelman RD,Zivi A,Riisnaes R,Malone MD,Sloane R,Alumkal JJ,Dickinson PA,Clack G,Elliott T.AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer - results of two parallel first-in-human phase I studies..Invest New Drugs2015;33:679-90

[149] Yamashita S,Chuang KL,Miyamoto H,Pang ST,Arai Y,Yeh S.ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors..Neoplasia2012;14:74-83 PMCID:PMC3281944

[150] Lai KP,Chang YJ,Yamashita S,Lee SO,Chang C.New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells..Am J Pathol2013;182:460-73 PMCID:PMC3562731

[151] Liu C,Zhu Y,Schwartz CT,Gao AC.Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer..Clin Cancer Res2014;20:3198-210 PMCID:PMC4058390

[152] Purushottamachar P,Martin MS,Ramalingam S.Identification of novel steroidal androgen receptor degrading agents inspired by galeterone 3β-imidazole carbamate..ACS Med Chem Lett2016;7:708-13 PMCID:PMC4948004

[153] Kwegyir-Afful AK,Purushottamachar P,Njar VC.Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo..Oncotarget2015;6:27440-60 PMCID:PMC4695001

[154] Bradbury RH,Rabow AA,Acton DG,Ballard P,Colclough N,Hancox UJ,Jude D,Mortlock AA.Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer..Bioorg Med Chem Lett2011;21:5442-5

[155] Gustafson JL,Cox CS,Buckley DL,Sundberg TB,Hines J,Norris JD.Small-molecule-mediated degradation of the androgen receptor through hydrophobic tagging..Angew Chem Int Ed Engl2015;54:9659-62 PMCID:PMC4547777

[156] Lai AC.Induced protein degradation: an emerging drug discovery paradigm..Nat Rev Drug Discov2017;16:101-14 PMCID:PMC5684876

[157] Chu FM,Gomella L,Somerville MC,Manyak MJ.A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer..Eur J Cancer2015;51:1555-69

[158] Hamid AR,Smit FP,Armandari I,Sweep FC,Schalken JA.Dutasteride and enzalutamide synergistically suppress prostate tumor cell proliferation..J Urol2015;193:1023-9

[159] Liu C,Zhu Y,Nadiminty N,Evans CP.Intracrine androgens and AKR1C3 activation confer resistance to enzalutamide in prostate cancer..Cancer Res2015;75:1413-22 PMCID:PMC4383695

[160] Liu C,Lou W,Evans CP.Inhibition of AKR1C3 activation overcomes resistance to abiraterone in advanced prostate cancer..Mol Cancer Ther2017;16:35-44

[161] Androgen receptor antagonist ARN-509, abiraterone acetate, prednisone, degarelix, and indomethacin in treating patients with localized prostate cancer before surgery. Available from: https://www.bioportfolio.com/resources/trial/162934/Androgen-Receptor-Antagonist-ARN-509-Abiraterone-Acetate-Prednisone-Degarelix-and-Indomethacin-in.html. [Last accessed on 13 Nov 2017]

[162] Anighoro A,Rastelli G.Polypharmacology: challenges and opportunities in drug discovery..J Med Chem2014;57:7874-87

[163] Boschi D,Cena C,Di Stilo A,Coruzzi G,Fruttero R.Multitarget drugs: synthesis and preliminary pharmacological characterization of zileuton analogues endowed with Dual 5-LO inhibitor and NO-dependent activities..Chem Med Chem2010;5:1444-9

[164] Chen M,Twenter BM,Christianson DW.Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer..Bioorg Med Chem Lett2012;22:3492-7 PMCID:PMC3348334

[165] Feau C,Kosinski A,Connelly M.Novel flufenamic acid analogues as inhibitors of androgen receptor mediated transcription..ACS Chem Biol2009;4:834-43 PMCID:PMC2763043

[166] Purushottamachar P,Gediya LK,Vasaitis TS,Ramalingam S,Njar VC.Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer..J Med Chem2013;56:4880-98 PMCID:PMC3959744

[167] Bruno RD,Gediya LK,Godbole AM,Brodie AMH.Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model..Steroids2011;76:1268-79 PMCID:PMC3171567

[168] Vasaitis T,Schayowitz A,Chopra P,Guo Z,Njar VC.Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer..Mol Cancer Ther2008;7:2348-57 PMCID:PMC2643345

[169] Tokai Pharmaceuticals Announces Clinical Update. Available from: http://www.businesswire.com/news/home/20160726005553/en/Tokai-Pharmaceuticals-Announces-Clinical-Update. [Last accessed on 13 Nov 2017]

[170] Li Z,Alyamani M,Dreicer R,Liu J,Auchus RJ.Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer..Nature2015;523:347-51 PMCID:PMC4506215

[171] Richards J,Hay CW,Wingate A,Pezaro C,Goodall J,McEwan IJ,Attard G.Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100..Cancer Res2012;72:2176-82 PMCID:PMC4281708

[172] Buttigliero C,Bertaglia V,Bironzo P,Scagliotti GV.Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer..Cancer Treat Rev2015;41:884-92

[173] Jernberg E,Bovinder YE,Crnalic S,Bergh A.Characterization of prostate cancer bone metastases according to expression levels of steroidogenic enzymes and androgen receptor splice variants..PLoS One2013;8:e77407 PMCID:PMC3820691

[174] Djusberg E,Thysell E,Lundberg P,Widmark A,Brattsand M.High levels of the AR-V7 splice variant and co-amplification of the golgi protein coding YIPF6 in AR amplified prostate cancer bone metastases..Prostate2017;77:625-38

[175] Hagberg Thulin M,Thulin P,Ohlsson C,Welén K.Osteoblasts promote castration-resistant prostate cancer by altering intratumoral steroidogenesis..Mol Cell Endocrinol2016;422:182-91

[176] Hofland J,Dits NF,van Leenders GJ,Schroder FH.Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer..Cancer Res2010;70:1256-64

[177] Pfeiffer MJ,Sedelaar JP.Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer..Mol Med2011;17:657-64 PMCID:PMC3146625

[178] Audet-Walsh E,Tam IS.Inverse regulation of DHT synthesis enzymes 5alpha-reductase types 1 and 2 by the androgen receptor in prostate cancer..Endocrinology2017;158:1015-21

[179] Luo J,Ewing CM,Isaacs WB.Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma..Prostate2003;57:134-9

[180] Thomas LN,Gupta R,Troyer DA,Rittmaster RS.Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer..Prostate2005;63:231-9

[181] Bjelfman C,Brekkan E,Egevad L,Andersson S.Differential gene expression of steroid 5 alpha-reductase 2 in core needle biopsies from malignant and benign prostatic tissue..J Clin Endocrinol Metab1997;82:2210-4

[182] Uemura M,Chung S,Okuyama A,Nakagawa H.Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer..Cancer Sci2008;99:81-6

[183] Feldman BJ.The development of androgen-independent prostate cancer..Nat Rev Cancer2001;1:34-45

[184] Hoang DT,Kilari D,Nevalainen MT.Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: opportunities for therapeutic targeting from multiple angles..Oncotarget2017;8:3724-45